Activity and tolerability of nilotinib: A retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant

Cancer

Volumn 116, Issue 19, 2010, Pages 4564-4572

  Koren Michowitz, Maya ^a   Le Coutre, Philipp ^b   Duyster, Justus ^c   Scheid, Christof ^d   Panayiotidis, Panayiotis ^e   Prejzner, Witold ^f   Rowe, Jacob M ^g   Schwarz, Michaela ^b   Goldschmidt, Neta ^h   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF ATHENS   (Greece)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g RAMBAM MEDICAL CENTER   (Israel)

^h HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Chronic myeloid leukemia; Imatinib; Nilotinib; Response prediction; Tyrosine kinase inhibitors

Indexed keywords

ABELSON KINASE; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACTERIAL INFECTION; BONE PAIN; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COHORT ANALYSIS; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FEVER; GENE MUTATION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERURICEMIA; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYCOSIS; NAUSEA AND VOMITING; OVERALL SURVIVAL; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QT PROLONGATION; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RETROSPECTIVE STUDIES;

EID: 77957590023     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25351     Document Type: Article

References (25)

1. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-1061.
2. Hochhaus AKS, Corbin AS, La Rosee P, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190-2196.
3. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005;11:4941-4947.
4. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood. 2006;108:1328-1333.
5. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-3546.
6. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008;111:1834-1839.
7. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551.
8. Giles FJ, Kantarjian HM, le Coutre P, et al. Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. J Clin Oncol. 2008;26:7017.
9. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res. 2008;14:5325-5331.
10. O'Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242-2249.
11. Vivante A, Amariglio N, Koren-Michowitz M, et al. Highthroughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations. Leukemia. 2007;21:1318-1321.
12. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
13. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
14. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
15. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27:4204-4210.
16. le Coutre PD, Giles F, Hochhaus A, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. ASH Annual Meeting Abstracts. 2008;112:3229.
17. Kantarjian HM, Giles F, Bhalla KN, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. ASH Annual Meeting Abstracts. 2008;112:3238.
18. Giles F, le Coutre PD, Bhalla KN, et al. Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase (CML-chronic phase) who failed prior imatinib and dasatinib therapy: updated results of a phase 2 study [abstract]. ASH Annual Meeting Abstracts. 2008;112:3234.
19. Branford S, Lawrence R, Fletcher L, Field C, Rudzki Z, Hughes T. The initial molecular response of chronic phase CML patients treated with second generation ABL inhibitor therapy after imatinib failure can predict inadequate response and provide indications for rational mutation screening [abstract]. ASH Annual Meeting Abstracts. 2008;112:331.
20. Fava C, Kantarjian HM, Jabbour E, et al. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009;13:5058-5063.
21. Hochhaus A, Kim D-W, Martinelli G, et al. Nilotinib efficacy according to baseline BCR-ABL mutations in patients with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. ASH Annual Meeting Abstracts. 2008;112:3216.
22. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
23. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood. 2007;109:5011-5015.
24. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27:469-471.
25. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141.